Nifty
:
25476.10
Sensex
:
83536.08
-46.40 (-0.18%)
-176.43 (-0.21%)
Nifty
Sensex
:
:
25476.10
83536.08
-46.40 (-0.18%)
-176.43 (-0.21%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
65/99

BSE: 500257 | NSE: LUPIN

NSE BSE
1914.20
09-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1933.4
  •  1965.5
  •  1906.9
  •  1922.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1578005
  •  3052569448.1
  •  2402.9
  •  1766.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 87,376.65
  • 26.63
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 89,310.97
  • 0.63%
  • 5.08

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.92%
  • 0.30%
  • 5.10%
  • FII
  • DII
  • Others
  • 21.46%
  • 23.90%
  • 2.32%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.59
  • 3.51
  • 6.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.46
  • 8.90
  • 77.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -2.25
  • 26.17
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.14
  • 35.91
  • 40.91

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.55
  • 4.01
  • 4.46

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.37
  • 18.28
  • 11.91

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
42.05
71.95
88.23
88.53
P/E Ratio
45.52
26.60
21.70
21.62
Revenue
19656
22192
25415
26685
EBITDA
3800
5278
6346
6331
Net Income
1914
3282
4021
4046
ROA
8.2
12.3
14.9
13.2
P/B Ratio
4.23
5.08
4.23
3.62
ROE
14.31
20.84
21.22
18.07
FCFF
2483
1192
3329
3712
FCFF Yield
2.76
1.32
3.7
4.12
Net Debt
1092
1246
-2061
-5232
BVPS
452.14
376.77
452.3
528.93

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
5,667.13
4,960.79
14.24%
5,767.71
5,197.41
10.97%
5,672.73
5,038.56
12.59%
5,600.33
4,814.06
16.33%
Expenses
4,345.96
3,963.94
9.64%
4,411.81
4,159.47
6.07%
4,332.37
4,120.80
5.13%
4,359.36
3,957.77
10.15%
EBITDA
1,321.17
996.85
32.53%
1,355.90
1,037.94
30.63%
1,340.36
917.76
46.05%
1,240.97
856.29
44.92%
EBIDTM
23.31%
20.09%
23.51%
19.97%
23.63%
18.21%
22.16%
17.79%
Other Income
56.95
29.25
94.70%
53.71
29.37
82.87%
42.29
40.40
4.68%
67.78
22.83
196.89%
Interest
89.10
71.29
24.98%
66.89
74.01
-9.62%
70.87
80.64
-12.12%
68.01
85.67
-20.61%
Depreciation
393.18
457.10
-13.98%
271.45
257.20
5.54%
256.92
247.85
3.66%
247.71
234.66
5.56%
PBT
895.84
497.71
79.99%
1,071.27
736.10
45.53%
1,054.86
629.67
67.53%
993.03
558.79
77.71%
Tax
113.46
129.49
-12.38%
212.41
117.40
80.93%
195.38
134.35
45.43%
187.49
105.46
77.78%
PAT
782.38
368.22
112.48%
858.86
618.70
38.82%
859.48
495.32
73.52%
805.54
453.33
77.69%
PATM
13.81%
7.42%
14.89%
11.90%
15.15%
9.83%
14.38%
9.42%
EPS
16.92
7.89
114.45%
18.74
13.46
39.23%
18.69
10.76
73.70%
17.57
9.94
76.76%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
22,707.90
20,010.82
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
Net Sales Growth
13.48%
20.25%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
 
Cost Of Goods Sold
6,842.25
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
Gross Profit
15,865.65
14,366.16
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
GP Margin
69.87%
71.79%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
Total Expenditure
17,449.50
16,221.71
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
Power & Fuel Cost
-
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
% Of Sales
-
2.46%
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
Employee Cost
-
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
% Of Sales
-
17.46%
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
Manufacturing Exp.
-
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
% Of Sales
-
13.68%
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
General & Admin Exp.
-
2,221.17
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
% Of Sales
-
11.10%
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
Selling & Distn. Exp.
-
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
% Of Sales
-
6.71%
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
Miscellaneous Exp.
-
286.55
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
835.48
% Of Sales
-
1.43%
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
EBITDA
5,258.40
3,789.11
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
EBITDA Margin
23.16%
18.94%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
Other Income
220.73
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
Interest
294.87
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
Depreciation
1,169.26
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
PBT
4,015.00
2,422.27
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
Tax
708.74
486.70
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
Tax Rate
17.65%
20.09%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
PAT
3,306.26
1,914.48
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
PAT before Minority Interest
3,281.62
1,935.57
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
Minority Interest
-24.64
-21.09
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
PAT Margin
14.56%
9.57%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
PAT Growth
70.82%
345.15%
-
-
-
-
146.92%
-90.28%
13.00%
-6.13%
 
EPS
72.41
41.93
9.42
-33.47
26.61
-5.99
13.40
5.43
55.83
49.41
52.63

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
Share Capital
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
Total Reserves
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
Non-Current Liabilities
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
Secured Loans
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
Unsecured Loans
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
Long Term Provisions
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
Current Liabilities
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
Trade Payables
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
Other Current Liabilities
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
Short Term Borrowings
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
Short Term Provisions
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
Total Liabilities
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
Net Block
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
Gross Block
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
Accumulated Depreciation
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
Non Current Assets
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
Capital Work in Progress
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
Non Current Investment
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
Long Term Loans & Adv.
277.52
620.92
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
Other Non Current Assets
90.95
57.70
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
Current Assets
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
Current Investments
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
Inventories
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
Sundry Debtors
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
Cash & Bank
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
Other Current Assets
1,752.23
1,519.98
497.54
556.89
1,717.86
1,769.95
1,711.95
1,191.01
1,241.22
534.98
Short Term Loans & Adv.
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
Net Current Assets
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
Total Assets
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
PBT
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
Adjustment
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
Changes in Working Capital
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
Cash after chg. in Working capital
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
Net Fixed Assets
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
Net Investments
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
Others
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
Cash from Financing Activity
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
Net Cash Inflow / Outflow
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
Opening Cash & Equivalents
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
Closing Cash & Equivalent
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
ROA
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
ROE
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
ROCE
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
Fixed Asset Turnover
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
2.16
Receivable days
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
72.65
Inventory Days
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
65.73
Payable days
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
Cash Conversion Cycle
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
Total Debt/Equity
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
Interest Cover
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Lupin signs license and supply agreement with Zentiva
    9th Jul 2025, 11:11 AM

    The agreement is for commercialization of the company’s biosimilar Certolizumab Pegol

    Read More
  • Lupin launches Ipratropium Bromide Nasal Solution in United States
    4th Jul 2025, 17:43 PM

    Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S.

    Read More
  • Lupin gets USFDA’s nod for Loteprednol Etabonate Ophthalmic Gel
    2nd Jul 2025, 09:07 AM

    Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity

    Read More
  • Lupin executes BTA for transfer of API R&D Division to Lupin Manufacturing Solutions
    1st Jul 2025, 11:53 AM

    In terms of the BTA, the said transaction has been completed and transfer of API R&D Division is effective from July 01, 2025

    Read More
  • Lupin executes BTA for transfer of OTC Business to LUPINLIFE Consumer Healthcare
    1st Jul 2025, 10:23 AM

    In terms of the BTA, the said transaction has been completed, and transfer of OTC Business is effective from July 01, 2025

    Read More
  • Lupin launches Prucalopride Tablets in United States
    26th Jun 2025, 16:30 PM

    Prucalopride Tablets, 1 mg, and 2 mg had estimated annual sales of $184 million in the U.S.

    Read More
  • Lupin gets USFDA’s nod for Prucalopride Tablets
    25th Jun 2025, 14:30 PM

    This product will be manufactured at Lupin’s Goa facility in India

    Read More
  • Lupin signs license and supply agreement with Sino Universal Pharmaceuticals
    16th Jun 2025, 11:10 AM

    This partnership will enable Lupin to expand its footprint in China

    Read More
  • Lupin gets USFDA’s approval for Oxcarbazepine ER tablets
    9th Jun 2025, 10:09 AM

    This product would be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin enters into license, supply agreement with SteinCares
    26th May 2025, 11:49 AM

    The companies have entered into agreement for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina

    Read More
  • Lupin, Honeywell move forward jointly with plans for HFO Technology in Inhalers
    20th May 2025, 14:51 PM

    Honeywell Solstice Air has the potential to prevent the release of high global warming potential molecules

    Read More
  • Lupin gets USFDA’s nod for Rivaroxaban Tablets
    15th May 2025, 16:30 PM

    This product will be manufactured at Lupin’s Aurangabad facility in India

    Read More
  • Lupin reports over two-fold jump in Q4 consolidated net profit
    15th May 2025, 12:00 PM

    The total consolidated income of the company increased by 14.71% at Rs 5,724.08 crore for Q4FY25

    Read More
  • Lupin launches Tolvaptan Tablets in United States
    13th May 2025, 14:44 PM

    The company holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

    Read More
  • Lupin launches Eslicarbazepine Acetate Tablets
    8th May 2025, 09:28 AM

    Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity

    Read More
  • Lupin gets USFDA’s nod for Tolvaptan Tablets
    24th Apr 2025, 12:00 PM

    Tolvaptan Tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company

    Read More
  • Lupin’s arm recalling 2,724 bottles of Clomipramine hydrochloride Capsules
    23rd Apr 2025, 16:00 PM

    The company initiated the Class II recall on April 18, 2025

    Read More
  • Lupin’s arm achieves NABL accreditation across all greenfield labs
    23rd Apr 2025, 14:30 PM

    This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL’s unwavering dedication to providing top-tier diagnostic services

    Read More
  • Lupin gets EIR from USFDA for injectable facility in Nagpur
    17th Apr 2025, 16:09 PM

    The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024

    Read More
  • Lupin’s arm acquires Renascience Pharma in United Kingdom
    3rd Apr 2025, 09:19 AM

    With this acquisition, Lupin Healthcare (UK) gains full ownership of Renascience which, going forward, will trade as its subsidiary

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.